Your browser doesn't support javascript.
Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history.
Ota, Kenji; Murakami, Satoshi; Ishihara, Kaori; Sasaki, Daisuke; Usui, Tetsuya; Mitsumoto-Kaseida, Fujiko; Sakamoto, Kei; Kosai, Kosuke; Hasegawa, Hiroo; Takazono, Takahiro; Furumoto, Akitsugu; Asoh, Norichika; Yoshimine, Hiroyuki; Sawai, Toyomitsu; Onizuka, Masanari; Makimoto, Noriaki; Izumikawa, Koichi; Mukae, Hiroshi; Kohno, Shigeru; Yanagihara, Katsunori.
  • Ota K; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Murakami S; Abbott Japan LLC, Tokyo, Japan.
  • Ishihara K; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Sasaki D; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Usui T; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Mitsumoto-Kaseida F; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Sakamoto K; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Kosai K; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Hasegawa H; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Takazono T; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Furumoto A; Juzenkai Hospital, Nagasaki, Japan.
  • Asoh N; Infectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Yoshimine H; Juzenkai Hospital, Nagasaki, Japan.
  • Sawai T; Inoue Hospital, Nagasaki, Japan.
  • Onizuka M; Nagasaki Harbor Medical Center, Nagasaki, Japan.
  • Makimoto N; Nagasaki Kita Tokushukai Hospital, Nagasaki, Japan.
  • Izumikawa K; Tagami Hospital, Nagasaki, Japan.
  • Mukae H; Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Kohno S; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Yanagihara K; Nagasaki University, Nagasaki, Japan.
Vaccine X ; 13: 100282, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2275148
ABSTRACT
The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Vaccine X Year: 2023 Document Type: Article Affiliation country: J.jvacx.2023.100282

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Vaccine X Year: 2023 Document Type: Article Affiliation country: J.jvacx.2023.100282